KIRSTEN WERNER: Open Payments
NPI 1518322767 · GRAND RAPIDS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,100 in 181 payments from 22 companies in 2025. Trend: 2023 $1,881 · 2024 $2,734 · 2025 $3,100
Food & beverage: $3,100
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 32 | $573 |
| ABBVIE INC. | 36 | $488 |
| Otsuka America Pharmaceutical, Inc. | 17 | $238 |
| PFIZER INC. | 10 | $185 |
| GlaxoSmithKline, LLC. | 11 | $179 |
| Neurocrine BioSciences, Inc. | 7 | $154 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $146 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 8 | $143 |
| AstraZeneca Pharmaceuticals LP | 7 | $143 |
| Lundbeck LLC | 5 | $137 |
Products named: REXULTI, Wegovy, VRAYLAR, TRELEGY ELLIPTA, UBRELVY, Ozempic, INGREZZA, CAPLYTA.
Industry payments across MI — which companies pay providers there.
